Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2025 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

kalvista pharmaceuticals - KALV

KALV

Close Chg Chg %
15.75 0.04 0.25%

Closed Market

15.79

+0.04 (0.25%)

Volume: 307.31K

Last Updated:

Dec 24, 2025, 1:00 PM EDT

Trade Now

Company Overview: kalvista pharmaceuticals - KALV

KALV Key Data

Open

$16.16

 Day Range

15.44 - 16.17

52 Week Range

7.30 - 17.30

 Market Cap

$796.10M

Shares Outstanding

50.55M

 Public Float

37.84M

Beta

-0.14

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$4.01

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

1.38M

  

KALV Performance

1 Week
 
 3.68%
 
1 Month
 
 9.12%
 
3 Months
 
 27.34%
 
1 Year
 
 85.11%
 
5 Years
 
 -9.87%
 

KALV Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 9
Full Ratings ➔

About kalvista pharmaceuticals - KALV

KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. Its product candidates are inhibitors of plasma kallikrein being developed for two indications: Sebetralstat for HAE and Factor XIIa. The company was founded by T. Andrew Crockett, Edward P. Feener, and Lloyd Paul Aiello on March 26, 2004 and is headquartered in Framingham, MA.

KALV At a Glance

KalVista Pharmaceuticals, Inc.
200 Crossing Boulevard
Framingham, Massachusetts 01702
Phone 1-857-999-0075 Revenue 0.00
Industry Pharmaceuticals: Major Net Income -183,444,000.00
Sector Health Technology Employees 270
Fiscal Year-end 04 / 2026
View SEC Filings

KALV Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio N/A
Price to Book Ratio 5.921
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -2.37
Enterprise Value to Sales N/A
Total Debt to Enterprise Value 0.246

KALV Efficiency

Revenue/Employee N/A
Income Per Employee -679,422.222
Receivables Turnover N/A
Total Asset Turnover N/A

KALV Liquidity

Current Ratio 5.351
Quick Ratio 5.351
Cash Ratio 4.884

KALV Profitability

Gross Margin N/A
Operating Margin N/A
Pretax Margin N/A
Net Margin N/A
Return on Assets -75.464
Return on Equity -121.497
Return on Total Capital -88.373
Return on Invested Capital -87.73

KALV Capital Structure

Total Debt to Total Equity 117.61
Total Debt to Total Capital 54.046
Total Debt to Total Assets 44.738
Long-Term Debt to Equity 115.537
Long-Term Debt to Total Capital 53.094
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Kalvista Pharmaceuticals - KALV

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
- - - -
-
Sales Growth
- - - -
-
Cost of Goods Sold (COGS) incl D&A
743.00K 802.00K 816.00K 941.00K
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
743.00K 802.00K 816.00K 941.00K
Depreciation
743.00K 802.00K 816.00K 941.00K
Amortization of Intangibles
- - - -
-
COGS Growth
+14.13% +7.94% +1.75% +15.32%
Gross Income
(743.00K) (802.00K) (816.00K) (941.00K)
Gross Income Growth
-14.13% -7.94% -1.75% -15.32%
Gross Profit Margin
- - - -
-
2022 2023 2024 2025 5-year trend
SG&A Expense
95.87M 110.07M 148.08M 192.07M
Research & Development
70.17M 80.28M 94.62M 76.72M
Other SG&A
25.70M 29.79M 53.46M 115.34M
SGA Growth
+67.39% +14.81% +34.53% +29.70%
Other Operating Expense
- - - -
-
Unusual Expense
- - - 1.76M
-
EBIT after Unusual Expense
(96.61M) (110.87M) (148.90M) (194.77M)
Non Operating Income/Expense
14.27M 17.96M 13.80M 15.49M
Non-Operating Interest Income
1.09M 2.23M 3.90M 6.43M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- - - 5.79M
-
Interest Expense Growth
- - - -
-
Gross Interest Expense
- - - 5.79M
-
Interest Capitalized
- - - -
-
Pretax Income
(82.34M) (92.91M) (135.10M) (185.07M)
Pretax Income Growth
-78.05% -12.83% -45.41% -36.99%
Pretax Margin
- - - -
-
Income Tax
- - (8.45M) (1.62M)
-
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - 8.45M 5.01M
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(82.34M) (92.91M) (126.64M) (183.44M)
Minority Interest Expense
- - - -
-
Net Income
(82.34M) (92.91M) (126.64M) (183.44M)
Net Income Growth
-78.05% -12.83% -36.31% -44.85%
Net Margin Growth
- - - -
-
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(82.34M) (92.91M) (126.64M) (183.44M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(82.34M) (92.91M) (126.64M) (183.44M)
EPS (Basic)
-3.3645 -3.3311 -3.4427 -3.6945
EPS (Basic) Growth
-38.92% +0.99% -3.35% -7.31%
Basic Shares Outstanding
24.47M 27.89M 36.79M 49.65M
EPS (Diluted)
-3.3645 -3.3311 -3.4427 -3.6945
EPS (Diluted) Growth
-38.92% +0.99% -3.35% -7.31%
Diluted Shares Outstanding
24.47M 27.89M 36.79M 49.65M
EBITDA
(95.87M) (110.07M) (148.08M) (192.07M)
EBITDA Growth
-67.39% -14.81% -34.53% -29.70%
EBITDA Margin
- - - -
-

Snapshot

Average Recommendation BUY Average Target Price 30.778
Number of Ratings 9 Current Quarters Estimate -0.837
FY Report Date 12 / 2025 Current Year's Estimate -2.89
Last Quarter’s Earnings N/A Median PE on CY Estimate N/A
Year Ago Earnings -3.69 Next Fiscal Year Estimate -2.037
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 9 5 9 9
Mean Estimate -0.84 -0.72 -2.89 -2.04
High Estimates -0.64 -0.43 -1.65 -0.44
Low Estimate -1.08 -1.12 -3.69 -3.58
Coefficient of Variance -17.99 -39.18 -21.24 -49.71

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 9 9 10
OVERWEIGHT 0 0 0
HOLD 0 0 0
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Insider Actions for Kalvista Pharmaceuticals - KALV

Date Name Shares Transaction Value
Dec 5, 2025 Nicole Sweeny Chief Commercial Officer 50,000 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Dec 5, 2025 Nicole Sweeny Chief Commercial Officer 81,250 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Dec 5, 2025 Nicole Sweeny Chief Commercial Officer 39,728 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $13.45 per share 534,341.60
Dec 5, 2025 Nicole Sweeny Chief Commercial Officer 43,541 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Dec 5, 2025 Nicole Sweeny Chief Commercial Officer 38,541 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
May 21, 2025 Christopher M. Yea CHIEF DEVELOPMENT OFFICER 98,157 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
May 21, 2025 Christopher M. Yea CHIEF DEVELOPMENT OFFICER 4,861 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
May 21, 2025 Christopher M. Yea CHIEF DEVELOPMENT OFFICER 7,095 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
May 21, 2025 Christopher M. Yea CHIEF DEVELOPMENT OFFICER 95,557 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $11.84 per share 1,131,394.88
May 21, 2025 Paul K. Audhya CHIEF MEDICAL OFFICER 8,056 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
May 21, 2025 Paul K. Audhya CHIEF MEDICAL OFFICER 9,675 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
May 21, 2025 Paul K. Audhya CHIEF MEDICAL OFFICER 106,611 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $11.84 per share 1,262,274.24
May 21, 2025 Paul K. Audhya CHIEF MEDICAL OFFICER 109,387 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
May 21, 2025 Benjamin L. Palleiko CHIEF EXECUTIVE OFFICER; Director 13,889 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
May 21, 2025 Benjamin L. Palleiko CHIEF EXECUTIVE OFFICER; Director 9,675 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
May 21, 2025 Benjamin L. Palleiko CHIEF EXECUTIVE OFFICER; Director 293,367 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $11.84 per share 3,473,465.28
May 21, 2025 Benjamin L. Palleiko CHIEF EXECUTIVE OFFICER; Director 297,175 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 26, 2025 Brian Piekos Chief Financial Officer 80,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 17, 2025 Venrock Associates 5,217,285 Open market or private purchase of non-derivative security Non-derivative transaction at $9.23 per share 48,155,540.55
Feb 17, 2025 Venrock Associates 5,278,985 Open market or private purchase of non-derivative security Non-derivative transaction at $9.33 per share 49,252,930.05

Kalvista Pharmaceuticals in the News